NCT07016750Phase 3Recruiting

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Study sponsor: Krystal Biotech, Inc. · KRYS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants16Estimated

Source updated2026-03-12Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-12 · 1 field changed

Enrollment · participant count

Recorded edit

− Previous value

+ Updated value

Check registry source

Posted 2026-02-27 · 3 fields changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: To evaluate the safety and tolerability of KB803.; measure: To evaluate the effect of ophthalmic KB803 versus placebo on frequency of corneal. abrasion symptoms.

+ Updated value

measure: To evaluate the safety and tolerability of KB803.; measure: To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms.

The saved outcome text may be shortened. Check the source for full wording.

Enrollment · participant count

Recorded edit

− Previous value

+ Updated value

Primary completion date

Recorded edit

− Previous value

2026-03

+ Updated value

2026-12

Check registry source

Study details

Conditions studied

Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis Bullosa

Treatments or interventions studied

KB803Biological
PlaceboDrug

Primary outcomes · main study measures

measure: To evaluate the safety and tolerability of KB803.; description: Number of subjects with treatment related adverse events as assessed by CTCAE v5.; timeFrame: 24 weeks; measure: To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms.; description: Average number of days per month with corneal abrasion symptoms.; timeFrame: 24 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history